Records containing: HER2-positive Breast Cancer

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2025-03-27
Selective Use of Observation After Lumpectomy and Sentinel Lymph Node Biopsy in Her-2 Positive Patients With Pathologic Complete Response to Neoadjuvant Chemotherapy
CLINICAL_TRIALS study record update · 2025-03-27
Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II
CLINICAL_TRIALS study record update · 2025-03-21
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
CLINICAL_TRIALS study record update · 2025-03-07
A Non Inferior, Randomized Controlled Phase II Clinical Study Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
CLINICAL_TRIALS study record update · 2025-03-03
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2025-02-27
A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer
CLINICAL_TRIALS study record update · 2025-02-20
De-escalation of Medical Therapies in HER2-positive Metastatic Breast Cancer in Long-term Persistent Response and Minimal Residual Disease Undetectable in Circulating Tumor DNA
CLINICAL_TRIALS study record update · 2025-02-18
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05): A Prospective, Single-arm, Multi-center Clinical Study
CLINICAL_TRIALS study record update · 2025-02-17
A Randomized, Open-label, Phase II Trial Comparing Neoadjuvant Endocrine Therapy in Combination with Trastuzumab, Pertuzumab +/- the PI3K Inhibitor Inavolisib in Patients with HER2-positive, HR-positive, PIK3CA Mutant Early Breast Cancer-GeparPiPPa
CLINICAL_TRIALS study record update · 2025-02-14
An Expanded Access Program Providing Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer in Single, Individually-approved Patients
CLINICAL_TRIALS study record update · 2025-01-31
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
CLINICAL_TRIALS study record update · 2025-01-20
Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative and HER2+ Metastatic Breast Cancer (MBC): a Single-centre Randomized Pilot Study
CLINICAL_TRIALS study record update · 2025-01-10
Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
CLINICAL_TRIALS study record update · 2025-01-01
A Single-arm, Multicenter, Real-world Observational Study of Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
CLINICAL_TRIALS study record update · 2024-12-30
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
CLINICAL_TRIALS study record update · 2024-12-27
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-18
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors
CLINICAL_TRIALS study record update · 2024-12-17
A Clinical Study of Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR Positive HER2 Positive Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-16
Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2024-12-13
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-13
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-11
Prospective, Multi-cohort, Exploratory Clinical Study of Pyrrotinib Maleate in HER2-positive Early Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-09
Cohort Study of Chemotherapy Combined With Targeted Adjuvant Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-09
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among T1c HER2 Positive Patients
CLINICAL_TRIALS study record update · 2024-12-04
De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade